TP53BP1 and cancer: Recent findings revealed that the combination therapy of 225Ac-PP-F11N, a minigastrin analog, with a P53BP1 histone deacetylase inhibitor exhibited synergistic effects by enhancing cytotoxicity and inducing DNA damage in overexpressed cholecystokinin B receptor cancer cells, leading to improved treatment outcomes in preclinical models [179].